MEDFORD, Mass., Sept. 11 /PRNewswire/ -- Serica Technologies, Inc., a growth-stage medical device company, has expanded its headquarters facilities, and recently completed the first manufacturing run of its novel biomaterial made from natural silk protein. Serica's new headquarters in Medford, MA, includes 22,000 square feet of state-of-the-art research and development laboratories, as well as manufacturing and administrative space. The facility is located convenient to Tufts University, where the company has ongoing collaborative research programs.
"This impressive facility is an excellent example of Massachusetts leading the way in this new century of the life sciences," said Senator Edward M. Kennedy. "Helping patients recover more quickly from surgery is an urgent medical need. The breakthrough new biomaterials being developed by Serica have great potential to improve the lives of countless patients across the country and throughout the world. I commend Serica for its pioneering new facility."
"We are entering an exciting new phase in the company's history, expanding our facilities and research programs to advance our technology platforms in orthopedic and reconstructive surgery, as well as a broad range of other applications in tissue repair," said Gregory H. Altman, Ph.D., President and CEO, Serica Technologies. "Serica is one of the few start-up companies committed to manufacturing -- we specialize in the proprietary processing of raw material to the packaging of finished product, combining state-of-the-art textile engineering and biomedical manufacturing capabilities."
Serica's new facilities feature nearly 12,000 square feet of research labs and a unique controlled environment manufacturing suite, which includes custom-designed textile processing equipment to achieve state-of-the-art production of its silk-based medical device product portfolio. Half of the company's 30 employees have received advanced scientific and medical degrees; additional hiring is planned for 2007.
"Serica's commitment to manufacturing our silk-based products from start to finish gives us a strategic advantage in that we have the flexibility and control to rapidly scale up our manufacturing to meet market needs and optimize our full product portfolio, while maintaining the highest standards of quality," said David Horan, Vice President of Operations.
"Our novel manufacturing processes and equipment have streamlined production, from months to just days. Our scientists excel at applying the oldest known biomaterial -- natural silk protein -- and well-established textile manufacturing principles, to cutting-edge medical device development," Horan added.
Dr. Altman founded Serica in 1998, after completing his undergraduate and graduate studies at Tufts University, where he ruptured his ACL playing varsity football. Following knee surgery, Dr. Altman experienced the debilitating side effects of ACL reconstruction. This experience inspired his doctoral work, during which time he developed the concept and technology that became the platform for the current Serica product line.
"With tremendous support from our investors, our collaborators at Tufts University's Department of Biomedical Engineering, the City of Medford and our landlord, Cummings Properties, we are able to accelerate our clinical development programs," added Altman. "We are truly grateful for their ongoing support."
About the Technology
The body's structural tissue can be destroyed, removed or weakened due to trauma, disease or aging. Serica is developing natural silk biomaterials designed to provide immediate, temporary stabilization to soft connective tissue structures -- such as ligaments and tendons -- following surgical repair.
The company's ligament grafts for ACL repair, surgical meshes and gels, are comprised of the fiber protein of the B. mori silkworm, which has centuries of human use. Using its proprietary technology, Serica's silk protein-based products can be bioresorbed in the body.
Serica's biomaterials are designed to act as "scaffolds" to provide support and relief to damaged tissues, promoting restored function. Serica is developing products for a wide variety of applications where current materials fail to meet the needs of clinicians and patients, including connective tissue repair of the knee, shoulder, abdomen, breast, neck and face.
Serica's lead product, the SeriACL(TM) graft, incorporating the company's biomaterial made from natural silk protein, is being studied as an option for ACL (anterior cruciate ligament) repair, a common knee injury currently requiring significant rehabilitation following surgery. A clinical trial with the SeriACL graft is opening in Europe during the fourth quarter of 2007. Studies to support U.S. registration are planned for next year.
About Serica Technologies Inc.
Serica Technologies, Inc., formerly Tissue Regeneration, Inc., is a growth-stage medical device company pioneering silk-based biomaterial platforms for tissue rejuvenation. Incorporated in 1998, Serica's proprietary products currently in preclinical and clinical development are being studied in the areas of orthopedic and sports medicine, aesthetic and reconstructive plastic surgery and other structural tissue repair needs, and drug delivery applications. Serica's team of engineers and scientists are located in a state-of-the-art 22,000-square-foot office, R&D and manufacturing facility in Medford, MA. For more information about Serica Technologies, please visit http://www.sericainc.com.
|SOURCE Serica Technologies, Inc.|
Copyright©2007 PR Newswire.
All rights reserved